Aardvark Therapeutics, Inc. Common Stock

AARDNASDAQ • USD
ThemeBiotech - Drug Development›Metabolic & Cardiometabolic
6.64 USD
↘ 0.17 (2.50%)🟢LIVE (AS OF 09:36 AM EDT)
🟢Market: OPEN

Aardvark Therapeutics, Inc. Common Stock (AARD) trades at $6.64 per share. The technical outlook is "Sell" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Aug 26, 2026.

Open?$6.83
High?$6.92
Low?$6.50
Prev. Close?$6.81
Volume?3.3K
Avg. Volume?138.0K
VWAP?$6.73
Rel. Volume?0.02x
Bid / Ask
Bid?$5.16 × 100
Ask?$7.98 × 100
Spread?$2.82
Midpoint?$6.57
Valuation & Ratios
Market Cap?149.0M
Shares Out?21.9M
Float?12.1M
Float %?55.5%
P/E Ratio?N/A
P/B Ratio?1.99
EPS?-$3.19
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Themes
Biotech - Drug Development›Metabolic & CardiometabolicBiotech - Drug Development›Rare Disease Therapeutics
Employees
28
Market Cap
149.0M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.aardvarktherapeutics.com
Listed
2025-02-13
Address
4370 LA JOLLA VILLAGE DRIVE
SAN DIEGO, CA 92122
Phone: (858) 225-7696
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
23
Short Sent.?
74
Piotroski F-Score?0/9Weak
Altman Z-Score?8.91Safe
Confidence?36%Very Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?5.04%Elevated
Short Interest?611.8K
Days to Cover?5.3
Free Float12.1M
Avg Daily Volume116.6K
Settlement Date2026-08-14
Financial Health
Current Ratio?12.63Strong
Quick Ratio?12.63Strong
Cash Ratio?11.56Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
74
1.99CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.0CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-93.4%WEAK▾
ROA?
S&P
3
-85.8%WEAK▾
Cash Flow & Enterprise
FCF?$-69412000
Enterprise Value?$75.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist